Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal fat apron14.03.02.028; 07.16.05.0080.000168%Not Available
Anal prolapse07.03.01.0080.000392%Not Available
Biliary obstruction09.02.02.0050.000224%Not Available
Brachiocephalic vein thrombosis12.02.01.032; 24.01.05.0130.000112%Not Available
Breast necrosis21.05.04.0160.000112%Not Available
Burning feet syndrome15.03.04.019; 23.06.05.010; 17.02.06.0380.000381%Not Available
Cancer fatigue16.32.03.035; 08.01.01.0150.000168%Not Available
Cardiac dysfunction02.11.01.0040.000112%Not Available
Cold dysaesthesia17.02.06.0390.000168%Not Available
Cryptitis07.08.03.0210.000504%Not Available
Discoloured vomit07.01.07.0170.000336%Not Available
Disease complication08.01.03.0870.000168%Not Available
Duodenal obstruction07.13.06.0020.000112%
Extramammary Paget's disease16.03.02.011; 23.08.02.0110.000168%Not Available
Fixed eruption10.01.01.037; 08.01.06.025; 23.03.05.0080.000280%Not Available
Gait inability17.02.05.069; 08.01.02.0110.001690%Not Available
Hepatic cytolysis09.01.07.0360.000280%Not Available
Hyperglycaemic hyperosmolar nonketotic syndrome17.02.04.022; 14.07.04.009; 05.07.04.0090.000839%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000448%Not Available
Infusion site hypoaesthesia17.02.06.048; 12.07.05.030; 08.02.05.0300.000112%Not Available
Intermenstrual bleeding21.01.01.015--Not Available
Intestinal pseudo-obstruction07.02.02.0200.000336%Not Available
Mucosal disorder08.01.06.0290.000974%Not Available
Myelodysplastic syndrome with excess blasts16.01.04.010; 01.10.04.0100.000112%Not Available
Myelosuppression01.03.03.0150.003022%Not Available
Myocardial injury02.04.02.0460.000112%Not Available
Neovascular age-related macular degeneration06.09.03.0330.000112%Not Available
Paraneoplastic dermatomyositis16.32.01.012; 15.06.01.022; 10.04.02.019; 23.03.02.0230.000168%Not Available
Pharyngo-oesophageal diverticulum22.04.05.029; 07.10.01.0040.000246%Not Available
Physical deconditioning08.01.03.0960.000224%Not Available
The 30th Page    First    Pre   30 31    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene